Holen Sie sich die Stockscreener-App
2.56
4.12%
-0.11
Handel nachbörslich:
2.70
0.14
+5.47%
Schlusskurs vom Vortag:
$2.67
Offen:
$2.7
24-Stunden-Volumen:
534.25K
Relative Volume:
1.54
Marktkapitalisierung:
$168.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.84M
KGV:
-5.2794
EPS:
-0.4849
Netto-Cashflow:
$-23.88M
1W Leistung:
-0.39%
1M Leistung:
-17.42%
6M Leistung:
-42.34%
1J Leistung:
+93.94%
1-Tages-Spanne:
$2.50
$2.77
1-Wochen-Bereich:
$2.50
$2.92
52-Wochen-Spanne:
$1.21
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.56 | 175.76M | 0 | -30.84M | -23.88M | -0.4849 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Galectin Therapeutics (GALT) Eps Diluted (TTM) - Zacks Investment Research
Galectin Therapeutics (GALT) upgraded to buy: What does it mean for the stock? - MSN
Galectin Therapeutics Inc. (PHPN.F) Analyst insights, Price targets and Recommendations - sg.finance.yahoo.com
Galectin Therapeutics (GALT) Receives Buy Rating: How Will This Impact the Shares? - Bitget
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
HC Wainwright Boosts FY2026 Earnings Estimate for Galectin Therapeutics - National Today
FY2026 Earnings Estimate for GALT Issued By HC Wainwright - marketbeat.com
Aug PostEarnings: Can Galectin Therapeutics Inc reach all time highs this year2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
What is HC Wainwright's Estimate for GALT Q1 Earnings? - marketbeat.com
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galectin Therapeutics (NASDAQ: GALT) launches $32.5M ATM; 3% agent fee - Stock Titan
Galectin Therapeutics Reports 2025 Financial Results, Advances Belapectin Program for MASH Cirrhosis, and Extends Cash Runway Through 2027 - Minichart
Galectin Therapeutics Reports 2025 Financial Results - National Today
Galectin Therapeutics Inc. (GALT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Galectin Therapeutics 2025 Annual Report: Clinical Trials, Regulatory Challenges, and Biopharma Industry Risks - Minichart
Galectin Therapeutics (NASDAQ:GALT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - marketbeat.com
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs - TradingView
With no approved MASH cirrhosis drugs, Galectin takes belapectin to FDA - stocktitan.net
NAVIGATE MASH data and funding risks at Galectin (NASDAQ: GALT) - Stock Titan
Belapectin data and $30.8M 2025 loss at Galectin (NASDAQ: GALT) - stocktitan.net
Galectin Therapeutics 10-K: R&D cuts reduce cash burn; cash runway to Apr 2027 - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
What makes Galectin Therapeutics Inc stock attractive today2026 Trade Ideas & Low Risk High Win Rate Picks - baoquankhu1.vn
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update - Bitget
Galectin Therapeutics Short Interest Rises 27% in March - National Today
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 27.0% in March - marketbeat.com
Risk Recap: Is Galectin Therapeutics Inc in a bullish channel2026 Historical Comparison & Risk Managed Investment Entry Signals - baoquankhu1.vn
Retail Trends: Is Galectin Therapeutics Inc gaining market share2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
Galectin Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Aug Gainers: Does Galectin Therapeutics Inc stock have upside surprise potential2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Galectin Therapeutics (FRA:PHPN) PB Ratio : (As of Mar. 25, 2026) - gurufocus.com
Galectin Therapeutics Inc. (GALT) Stock forecasts - Yahoo Finance UK
Galectin Therapeutics (GALT) Projected to Post Earnings on Monday - Defense World
Wall Street Recap: What makes Galectin Therapeutics Inc stock attractive today - baoquankhu1.vn
Galectin Therapeutics Stock (ISIN: US3631621074) Faces Investor Scrutiny Amid Legal Probe and Earnin - AD HOC NEWS
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board - The Globe and Mail
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps - Defense World
Galectin Therapeutics Appoints Dr. Henry Brem to Board, Advancing Belapectin for MASH Cirrhosis and Cancer Therapies - Minichart
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board By Investing.com - Investing.com India
Galectin Therapeutics Inc. Appoints Henry Brem, M.D. as Independent Director to Board of Directors - marketscreener.com
Sentiment Recap: Is Galectin Therapeutics Inc forming a double bottom2026 Trade Ideas & Consistent Growth Equity Picks - baoquankhu1.vn
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board - Investing.com
Galectin Therapeutics (GALT) director awarded 60,000 stock options at $3.1600 - Stock Titan
Director Henry Brem joins Galectin (GALT) board and reports zero share ownership - Stock Titan
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. - Bitget
Henry Brem, M.D. joins Galectin Therapeutics (GALT) Board as independent director - Stock Titan
Portfolio Shifts: Whats the outlook for Galectin Therapeutics Incs sectorTake Profit & Accurate Entry/Exit Alerts - baoquankhu1.vn
Recap Report: Is Galectin Therapeutics Inc forming a double bottomQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Take Profit: Does Galectin Therapeutics Inc have a sustainable dividendJuly 2025 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Galectin Therapeutics Inc-Aktie (GALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
| Jamil Khurram | Chief Medical Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
60,000 |
| Jamil Khurram | Chief Medical Officer |
Jan 05 '26 |
Sale |
3.90 |
25,499 |
99,408 |
21,446 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):